Director/PDMR Shareholding – Exercise of Options and Total Voting Rights
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted in total 1,691,013 new ordinary shares of 4 pence each in the capital of the Company (“Ordinary Shares”). This is following the exercise of share options under the Company’s Third Unapproved Scheme by William Rhodes and Jeremy Millard, both Non-Executive Directors, and, under the Company’s EMI Option Scheme by Jag Grewal, Commercial Director and Kieron Harbinson, Group Finance Director (together the “Exercising Directors”).
In addition to the above dealings by the Exercising Directors, the Company has also received valid notices to exercise a further 74,347 share options from employees under the Company’s Sharesave scheme. Of this amount, 5,869 Ordinary Shares were exercised and subsequently sold by Jamie Yexley, Operations Director and PDMR of the Company, at a price of 82.25 pence per Ordinary Share, following this transaction his holding in the Company remains unchanged.
Further to the exercise of share options by the Exercising Directors as detailed above, the Company announces that the Exercising Directors have subsequently sold in aggregate 1,616,666 new Ordinary Shares at an average price of 87.28 pence per Ordinary Share. Additionally, Kieron Harbinson has notified the Company that he has sold a further 175,000 Ordinary Shares in the Company at an average price of 89.76 pence per Ordinary Share. As a consequence, the equity interests of the Exercising Directors following the above transactions are as follows:
Application will be made to the London Stock Exchange for the 1,691,013 new Ordinary Shares to be admitted to trading on AIM (“Admission”) and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 19 February 2021.
Following Admission, the total number of Ordinary Shares in issue will be 181,758,167 and the total number of voting rights will therefore be 181,758,167. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned